Results 261 to 270 of about 12,220,634 (288)
Some of the next articles are maybe not open access.
Hemodynamic and Exercise Effects of Phosphodiesterase 5 Inhibitors
The American Journal of Cardiology, 2005Phosphodiesterase 5 (PDE5) inhibitors have modest nitrate-like hemodynamic effects, lowering wedge pressure, pulmonary artery pressure, and systolic and diastolic arterial pressure. At rest, decreases in arterial pressure averaging 9/8 mm Hg may increase to 12/5 mm Hg as a result of the vasodilatory response, but no clinical adverse effects have been ...
openaire +2 more sources
Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia
Current Opinion in Urology, 2010Benign prostatic hyperplasia (BPH) is prevalent in old men and often results in lower urinary tract symptoms (LUTS). Phosphodiesterase-5 (PDE5) inhibitors increase intracellular concentrations of cyclic guanosine monophosphate. PDE5 inhibitors (sildenafil, tadalafil, vardenafil, etc.) are first-line treatments for erectile dysfunction.
openaire +2 more sources
Phosphodiesterase 5 inhibitors and adrenal incidentalomas
Medical Hypotheses, 2019Ioannis, Ilias, Lina, Zabuliene
openaire +2 more sources
Pharmacology of phosphodiesterase 5 inhibitors.
The Canadian journal of urology, 2003The phosphodiesterase enzymes, of at least 11 types, are ubiquitous throughout the body, and perform a variety of functions. Phosphodiesterase type 5 (PDE5) is the predominant enzyme in the corpus cavernosum, and plays a crucial role in penile erection.
openaire +1 more source
Phase 4 Studies on Phosphodiesterase 5 Inhibitors
JAMA Ophthalmology, 2022Brian L, VanderBeek, Maureen G, Maguire
openaire +2 more sources
Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?
International Journal of Molecular Sciences, 2021Daniela Mokrá, Juraj Mokry
exaly
Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis
European Urology Focus, 2017Marrissa Martyn-St James +2 more
exaly